4 May 2020 - Truxima is also now available for the treatment of granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.

Earlier this year, the Centers for Medicare and Medicaid Services (CMS) granted pass-through status for TRUXIMA in the hospital outpatient setting. The Wholesale Acquisition Cost (WAC or “list price”) for Truxima will be 10% lower than the reference product. Truxima is expected to be available through primary wholesalers at a WAC of $845.55 per 100 mg vial and $4,227.75 per 500 mg vial. Actual costs to individual patients and providers for Truxima are anticipated to be lower than WAC because WAC does not account for additional rebates and discounts that may apply. Savings on out-of-pocket costs may vary depending on the patient’s insurance payer and eligibility for participation in the assistance program.

Read Teva Pharmaceuticals press release